An Open-label Long-term Extension Trial From Late Phase II of SPM 962 (243-07-003) in Patients With Restless Legs Syndrome

Trial Profile

An Open-label Long-term Extension Trial From Late Phase II of SPM 962 (243-07-003) in Patients With Restless Legs Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top